news
METIS meets primary endpoint
The phase 3 METIS clinical trial demonstrated a statistically significant improvement in time to intracranial progression for patients treated with Tumor Treating Fields therapy and supportive care compared to supportive care alone in the treatment of patients with brain metastases from non-small cell lung cancer following stereotactic radiosurgery.
learn morenews
FDA PMA application update
Our Premarket Approval application seeking approval for the use of Tumor Treating Fields therapy together with standard systemic therapies for the treatment of non-small cell lung cancer, following progression on or after platinum-based therapy, has been accepted for filing by the U.S. FDA.
learn morenews
TRIDENT enrollment complete
The final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio® concurrent with radiation therapy and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma.
learn moreFrank Leonard, President of Novocure Oncology, is on the new episode of the Rare Enough podcast hosted by DJ Stewart, @HeadfortheCure community outreach coordinator. https://headforthecure.org/rare-enough-podcast/ #oncology #leadership #patientforward #WeAreNovocure
Our team had a great week at #AACR24 in San Diego, where we shared some of the latest scientific research on Tumor Treating Fields (#TTFields) therapy.
Learn more about us: http://novocure.com
#oncology #innovation #WeAreNovocure #patientforward
Meet Leonardo Lustgarten, Medical Director and Lead, Neurosurgery and Neuro-Oncology. He's in San Diego for the @AACR Annual Meeting.
Stop by Booth 719 or visit us online to learn more about our therapy. http://tumortreatingfieldstherapy.com
#WeAreNovocure #TTFields #AACR24 #oncology
Today we announced that 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (@AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. https://www.novocure.com/novocure-announces-20-presentations-on-tumor-treating-fields-highlighting-preclinical-effects-in-pancreatic-cancer-and-immune-effects-at-american-association-for-cancer-research-aacr-annual-meetin/
#AACR24 #TTFields #oncology
We will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. https://www.novocure.com/novocure-to-report-first-quarter-2024-financial-results/ #earnings #oncology
The phase 3 METIS clinical trial in brain metastases from non-small cell lung cancer following stereotactic radiosurgery met its primary endpoint. https://www.novocure.com/metis-phase-3-clinical-trial-met-primary-endpoint-demonstrating-a-statistically-significant-extension-in-time-to-intracranial-progression-for-patients-with-brain-metastases-from-non-small-cell-lung-c/ #oncology #clinicaltrials